surmount-1 tirzepatide non-diabetic weight loss for the Maintenance of Body Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity SURMOUNT 1 // Three-Year Obesty

Recently, a phase II multicentre, double-blind, randomized controlled trial including 338 adults with obesity were administered retatrutide (1, 2 mg starting dose increased to 4, 2 mg starting dose increased to 8, 2 mg starting dose increased to 12 mg) compared to placebo over 48 weeks [64]

Consistent with this, exendin-P5, which induces faster kinetics in G protein activation and cAMP production, exhibits higher cAMP efficacy than GLP-1 and exendin-4, as indicated by a greater pEC 50 /pIC 50 ratio when comparing cAMP and binding studies 13

There is also little evidence to suggest that these remedies are safe and effective

At Classy Aesthetics Wellness, we offer medically supervised treatments that support healthy weight management